BioVie, Inc. Common Stock (BIVI)

Price$1.49

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-4.12%

Price vs S&P 500 (4W)-20.45%

VGM Score37.35

Market Capitalization$10.71M

All Metrics

Book Value / Share (Quarterly)$2.07

P/TBV (Annual)0.91x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.72

Price vs S&P 500 (YTD)11.48%

EPS (TTM)$-4.32

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-4.32

EPS (Annual)$-11.87

ROI (Annual)-92.27%

Cash / Share (Quarterly)$1.74

ROA (Last FY)-81.36%

EBITD / Share (TTM)$-3.61

ROE (5Y Avg)-783.38%

Cash Flow / Share (Annual)$-9.94

P/B Ratio0.69x

P/B Ratio (Quarterly)0.68x

Net Income / Employee (Annual)$-1,349,400

Net Interest Coverage (TTM)-8.70x

ROA (TTM)-90.12%

EPS Incl Extra (Annual)$-11.87

Current Ratio (Annual)9.10x

Quick Ratio (Quarterly)9.02x

3-Month Avg Trading Volume0.09M

52-Week Price Return-86.60%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.07

52-Week High$12.10

EPS Excl Extra (Annual)$-11.87

Tangible BV CAGR (5Y)100.59%

26-Week Price Return11.81%

Quick Ratio (Annual)8.64x

13-Week Price Return11.81%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.97x

Enterprise Value$-2.39M

Book Value / Share Growth (5Y)80.07%

Revenue / Employee (Annual)$0

Cash / Share (Annual)$9.17

3-Month Return Std Dev75.38%

Net Income / Employee (TTM)$-1,532,000

ROE (Last FY)-92.27%

Net Interest Coverage (Annual)-32.25x

EPS Basic Excl Extra (Annual)$-11.87

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.32

ROI (TTM)-101.09%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.84

Price vs S&P 500 (52W)-114.81%

Year-to-Date Return22.41%

5-Day Price Return-6.58%

EPS Normalized (Annual)$-11.87

ROA (5Y Avg)-526.91%

Month-to-Date Return-13.94%

Cash Flow / Share (TTM)$-1.44

EBITD / Share (Annual)$-12.07

LT Debt / Equity (Annual)0.34x

ROI (5Y Avg)-631.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.32

P/TBV (Quarterly)0.68x

P/B Ratio (Annual)0.90x

Book Value / Share (Annual)$9.93

Price vs S&P 500 (13W)2.06%

Beta0.70x

Revenue / Share (TTM)$0.00

ROE (TTM)-101.09%

52-Week Low$1.06

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q3 26-0.70est. -0.74

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BIVIBioVie, Inc. Common Stock	—	—	D	$1.49
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. Its lead program, NE3107, is advancing through Phase 3 clinical trials for mild to moderate Alzheimer's disease. BIV201 targets life-threatening complications of advanced liver disease, including cirrhosis from hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver injury.